Allecra Therapeutics

What Allecra Therapeutics does

Allecra Therapeutics is a biopharmaceutical company founded in 2013 and headquartered in Lörrach, Germany, with a wholly owned French subsidiary (Allecra Therapeutics SAS) in Saint-Louis, France. The company develops novel therapies to combat multi-drug-resistant bacterial infections, with a primary focus on Extended-Spectrum Beta-Lactamase (ESBL)-producing Gram-negative pathogens. Its lead product, EXBLIFEP (cefepime/enmetazobactam), combines a fourth-generation cephalosporin with a proprietary beta-lactamase inhibitor (enmetazobactam) — a tazobactam derivative featuring a strategically placed methyl group and zwitterionic structure that enhances periplasmic penetration and provides superior activity against ESBLs. The combination demonstrated superiority over piperacillin-tazobactam in the Phase 3 ALLIUM trial (79.1% vs 58.9% overall success rate in cUTIs) and received FDA approval in February 2024.

Allecra's business model is built on regional licensing and supply agreements with established pharmaceutical partners for global commercialization: ADVANZ PHARMA holds exclusive rights for Europe, Acino for the Gulf Cooperation Council countries and South Africa, and Shanghai Haini Pharmaceutical for Greater China. Allecra retained direct U.S. rights and sought additional regional partners for unpartnered territories. The company maintained a small operational footprint of 1-10 employees, consistent with an asset-light, licensing-oriented clinical-stage structure. Funding totaled approximately $44.4 million across two disclosed rounds (2013 and 2016), led by Andera Partners, Forbion, Delos Capital, EMBL Ventures, BioMedPartners, and Xeraya Capital, with additional French public funding (Bpifrance and Région Alsace) supporting its French subsidiary.

In October 2025, Allecra was acquired by Orchid Pharma Limited, an Indian pharmaceutical company that reacquired 100% global rights to enmetazobactam. The acquisition transitioned Orchid from a royalty-earning licensor to sole proprietor of EXBLIFEP, which Orchid values at over $1 billion in projected peak sales. This made enmetazobactam the first India-invented New Chemical Entity to receive USFDA approval for a combination antibiotic.

Name

Allecra Therapeutics

Legal name

Allecra Therapeutics GmbH

Website

https://allecra.com

Company type

Private

Founded year

2013

Operating status

Operating

Headcount range

1–10 employees

Short description

Allecra Therapeutics is a biopharmaceutical company that developed EXBLIFEP (cefepime/enmetazobactam), a novel antibiotic combination approved by the FDA in February 2024 to treat complicated urinary tract infections caused by ESBL-producing bacteria. It commercialized the drug through regional licensing partnerships with hospital and infectious disease specialists.

Ownership category

akta.pro rank

Headquarters

HQ city

Weil Am Rhein

HQ country

Germany

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Licensing and Supply Agreements: Allecra generates revenue through regional licensing and supply agreements with commercial partners for EXBLIFEP/Orblicef. Partners include Acino (GCC and South Africa), ADVANZ PHARMA (Europe), and Shanghai Haini Pharmaceutical (Greater China). Allecra supplies product to its licensees.
2. Antibiotic Sales (Post-Acquisition): Following Orchid Pharma's October 2025 acquisition of Allecra Therapeutics, enmetazobactam (as Exblifep/Orblicef) became an approved drug under Orchid's direct commercial control. The combination drug is valued at over $1 billion in projected peak sales.

Go-to-market motion2 records

Distribution channels4 records

Marketing channels3 records

Core offering

Allecra Therapeutics develops and commercializes novel antibiotic therapies targeting multi-drug-resistant bacterial infections. Its lead product, EXBLIFEP® (cefepime/enmetazobactam), combines a fourth-generation cephalosporin with a proprietary novel beta-lactamase inhibitor to treat complicated urinary tract infections and other infections caused by ESBL-producing Gram-negative pathogens. The drug received FDA approval in February 2024 following a successful Phase 3 ALLIUM trial demonstrating superiority over piperacillin-tazobactam.

Product overview

Allecra Therapeutics is a clinical-stage biopharmaceutical company with a focused product portfolio consisting of its lead antibiotic product EXBLIFEP® (cefepime/enmetazobactam), a novel β-lactam/β-lactamase inhibitor combination. Enmetazobactam is the proprietary β-lactamase inhibitor component that addresses Extended-Spectrum β-lactam resistant pathogens (ESBLs). The company develops therapies to combat antibiotic resistance through overcoming emergent resistance mechanisms. The company has licensing agreements for regional commercialization including with ADVANZ PHARMA (Europe), Acino (Gulf Cooperation Council and South Africa), and Shanghai Haini Pharmaceutical (Greater China).

Differentiator

Problem solved

Functional benefit

Brands

• EXBLIFEP®: Brand name for cefepime/enmetazobactam combination drug approved for treatment of complicated urinary tract infections. Also marketed as Orblicef™ in some markets.

Products and services

• EXBLIFEP® (Cefepime/Enmetazobactam) A novel antibiotic combination drug consisting of cefepime (4th generation cephalosporin) and enmetazobactam (novel beta-lactamase inhibitor) for treating complicated urinary tract infections (cUTIs), hospital-acquired pneumonia, and other serious Gram-negative bacterial infections caused by ESBL-producing pathogens. FDA-approved in February 2024.
• Enmetazobactam A novel proprietary beta-lactamase inhibitor developed by Allecra Therapeutics with potent activity against Class A serine beta-lactamases, specifically Extended-Spectrum beta-lactamases (ESBLs). It is a derivative of tazobactam with enhanced potency, zwitterionic structure for better periplasmic penetration, and extended half-life. Designed for use in combination with cefepime.

Quantifiable outcome

• 79.1% overall success rate for cefepime/enmetazobactam vs 58.9% for piperacillin-tazobactam (21.2% absolute improvement) in complicated urinary tract infections at test-of-cure visit.
• +3 more outcomes

Segments1 record

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

Three partnerships are on record, tiered core.

• AcinocoreChannel Partner/ Reseller/ Distributor · 24 June 2024Exclusive licensing and supply agreement for Allecra's novel antibiotic EXBLIFEP in Gulf Cooperation Council (GCC) countries and South Africa. Acino is a Swiss pharmaceutical company specializing in licensed-in branded medications for emerging markets.
• ADVANZ PHARMAcoreChannel Partner/ Reseller/ Distributor · 13 January 2022Exclusive license and supply agreement for Allecra's antibiotic cefepime/enmetazobactam in Europe. ADVANZ PHARMA is a pan-European specialty pharma company focused on hospital and critical care medicines.
• Shanghai Haini PharmaceuticalcoreChannel Partner/ Reseller/ Distributor · 21 December 2020Exclusive licensing agreement for cefepime/enmetazobactam for Greater China. Shanghai Haini Pharmaceutical is a Chinese pharmaceutical company focused on licensing and commercializing innovative medicines in China.

Scale indicators5 records

Recent moves7 records

Expansion highlights4 records

Broad incumbents

• Pfizer: Through its acquisition of Allergan's infectious disease unit and Zavicefta (ceftazidime-avibactam), Pfizer competes directly with EXBLIFEP® in ESBL and carbapenem-resistant indications.
• Shionogi: Large Japanese pharma with the cefiderocol franchise (Fetcroja) — a competing siderophore cephalosporin approved for resistant Gram-negative infections. Overlaps with EXBLIFEP® in target patient populations.
• Merck & Co. Markets Zerbaxa (ceftolozane-tazobactam), a direct competitor to cefepime/enmetazobactam for cUTI and intra-abdominal infections, overlapping with Allecra's lead indication.

Direct peers

• Entasis Therapeutics: Anti-infective developer of beta-lactam/beta-lactamase inhibitor combinations targeting resistant Gram-negative pathogens, with a structure analogous to Allecra's enmetazobactam program.
• Paratek Pharmaceuticals: Small/mid-cap anti-infective developer of tetracycline-class antibiotics (Nuzyra) for community-acquired pneumonia and skin infections. Operates with a similar specialty sales force model.
• Iterum Therapeutics: Small-cap anti-infective company developing sulopenem, an oral and IV penem antibiotic for uUTI/cUTI and complicated intra-abdominal infections. Targets similar carbapenem-sparing use cases.
• VenatoRx Pharmaceuticals: Clinical-stage antibiotic developer focused on beta-lactam/beta-lactamase inhibitor combinations for resistant Gram-negative infections. Closely comparable in size, stage and therapeutic target to Allecra.
• Nabriva Therapeutics: Specialty anti-infective company commercializing a recently FDA-approved antibiotic for community-acquired pneumonia and cUTI indications; comparable business model and target prescribers.
• Tetraphase Biosciences: Was a clinical-stage developer of eravacycline (Xerava) for serious infections, an earlier vintage equivalent of Allecra — illustrates the typical size, capital needs, and commercial-build profile for this category.

Others

• Shionogi B. V. / Melinta Therapeutics (Cempra): Adjacent anti-infective specialty players in the same small-cap antibiotic commercialization cohort historically competing in cUTI and respiratory infection markets; comparable in therapeutic positioning though trajectories diverged.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/allecra-therapeutics

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Subsidiaries1 record

Funding overview

Funding rounds2 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Allecra Therapeutics